Jeffrey Laurence, M.D.,
Latest by Jeffrey Laurence, M.D.,
Steven Deeks, M.D., and colleagues seek to define the frequency of "post-treatment controllers," who maintain control of HIV growth after discontinuing antiretroviral therapy.
Researchers have demonstrated that HIV latency can be maintained in actively growing cells, a finding that may open new avenues to abolishing latency.
A report on three other cases of HIV-infected individuals receiving stem cell transplants indicates the likely role that CCR5 mutation plays in HIV remission or cure.
Using a test tube model, researchers have been able to link specific non-coding RNAs to a group of proteins involved in establishing HIV latency.
Antibodies could potentially be a less toxic alternative to ART, if they prove to be effective in preventing early HIV infection in humans. This may be particularly important over the long periods of breastfeeding typical of many cultures.
It is now apparent that one of the very first immunologic events early after infection is severe depletion in the intestines of certain specialized T cells, Th17 and Th22.
Most animal and test-tube models for eliminating latent reservoirs of HIV -- the major impediment to an HIV cure -- suggest that simply trying to awaken the latent virus and using standard antiretroviral therapy will not be enough to completely eradi...
Most infants breastfed by an HIV-positive woman do not become infected. It has long been known that components of human breast milk from HIV-negative mothers can inhibit the growth of HIV in the test tube, indicating that HIV-specific antibodies in m...
Our immune systems offer a very rapid, non-specific first line of defense against invading viruses. Researchers recently examined the role of one of these early defenses in the control of HIV.
Researchers address what might be needed to boost a personâ€™s own immune system to facilitate eradication of HIV reservoirs.